Core Insights - Silo Pharma, Inc. has received a Japanese patent for its lead asset SPC-15, an intranasal treatment for post-traumatic stress disorder (PTSD), which enhances its intellectual property portfolio [1][2] - The company is collaborating with Columbia University for the development of SPC-15, which is a serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders [2][3] - Silo Pharma's therapeutic focus includes addressing conditions such as PTSD, chronic pain, and central nervous system diseases, with a diverse portfolio of innovative programs [3] Patent and Intellectual Property - The Japan Patent Office granted patent number 7683882 to Columbia University for the invention titled "Prophylactic efficacy of serotonin 4 receptor agonists against stress," which is exclusively licensed to Silo [1] - This patent adds to Silo's international intellectual property portfolio, reinforcing the protection for SPC-15 [2] Product Development - SPC-15 is positioned for potential eligibility under the FDA's streamlined 505(b)(2) regulatory pathway, which could expedite its approval process [2] - The company is conducting preclinical studies in collaboration with Columbia University and holds exclusive global rights for the development and commercialization of SPC-15 [2] Company Overview - Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company [3] - The company's portfolio includes other programs such as SP-26 for fibromyalgia and chronic pain, as well as preclinical assets targeting Alzheimer's disease and multiple sclerosis [3]